On February 22, 2022, Beijing tricision Biotech Co., Ltd. (tricision) and Mingdu Zhiyun (Zhejiang) Technology Co., Ltd. (Mingdu Zhiyun) held a strategic cooperation signing ceremony in Beijing, embarking on a new collaborative journey. Mr. Liu Dong, CEO of tricision, and Mr. Xing Jie, Co-founder and CEO of Mingdu Zhiyun, signed the strategic agreement on behalf of their respective companies to jointly promote pharmaceutical informatization, digitalization, and intelligent ecosystem transformation.

The pharmaceutical industry is a critical sector for national welfare and people's livelihoods, closely tied to economic development and public health. Against the backdrop of Industry 4.0, Made in China 2025, and the promotion of "informatization-industrialization" integration across industries, informatization-driven pharmaceutical industry development is a key future direction. Through this partnership, both parties will leverage their respective advantages and market opportunities to drive deeper development, making drug R&D processes more controllable and predictable through efficient collaboration and flexible service models.

As a company rooted in mRNA immunotherapy drug development, tricision is committed to advancing informatization with innovative thinking, building key capabilities through digital tools, and synergizing with other business areas to support mRNA innovation and industrial development. Through this collaboration with Mingdu Zhiyun, tricision will build a compliant, intelligent data collection and analysis management system—providing robust evidence for scientific decision-making, improving R&D efficiency and quality, effectively mitigating project risks, completing digital system construction, and achieving overall digital top-level planning and AI-empowered pharmaceutical innovation.

Mr. Liu Dong stated: "tricision has long been deeply engaged in the mRNA technology platform, committed to technological breakthroughs and industrial advancement in immunotherapy—providing excellent clinical solutions for cancer, infectious diseases, and genetic disorders. We are pleased to establish a comprehensive strategic partnership with Mingdu Zhiyun. Leveraging Mingdu Zhiyun's innovative solutions in R&D, manufacturing, and quality, we will continue to enhance tricision's digital and intelligent management capabilities, continuously strengthen efficient coordination between product R&D and manufacturing, and further accelerate tricision's growth."

Mr. Xing Jie commented: "As a digital transformation service provider in the life sciences field, Mingdu Zhiyun focuses on creating solutions covering the entire industry lifecycle—including smart R&D, smart quality, smart production, and smart logistics—to support rapid growth of innovative R&D enterprises and seize the initiative in the digital space. Mingdu is delighted to partner with tricision. Through multi-dimensional informatization service models, we will build a comprehensive, flexible, and highly scalable digital factory, establishing a digital foundation for compliance and safety in R&D and manufacturing operations."

About tricision

Founded in 2015, Beijing tricision Biotech Co., Ltd. is a legally registered biopharmaceutical enterprise focused on mRNA information drug technology innovation and product R&D. Its wholly-owned subsidiary, tricision Biotech (Zhuhai) Co., Ltd., was established in 2018. tricision upholds the mission of "protecting human life and health through nucleic acid information technology," with the goal of "building a leading integrated mRNA platform."

About Mingdu Zhiyun

Mingdu Zhiyun (Zhejiang) Technology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to providing digital transformation services in the life sciences. With the mission of "protecting every medicine and every patient," the Company's digital strategy encompasses smart R&D, smart production, future factories, industry brain, and smart regulatory collaboration. It has assembled an experienced team of "Biology + Digital" deeply integrated talents. Mingdu Zhiyun applies cloud computing, big data, IoT, AI, and digital twin technologies to deliver a full-stack digital product matrix covering R&D, quality, production, and logistics—committed to compliance, quality, safety, and supporting the digital and intelligent transformation of China's pharmaceutical industry.